Electroporation-mediated IL-12 gene therapy in a transplantable canine cancer model.
Interleukin-12 (IL-12) is effective in treating many types of rodent tumors, but has been unsuccessful in most human clinical trials, suggesting that animal models of more clinical relevance are required for evaluating human cancer immunotherapy. Herein, we report on the effectiveness of gene therapy with plasmid encoding human IL-12 (pIL-12) through in vivo electroporation in the treatment of beagles with a canine tumor, the canine transmissible venereal tumor (CTVT). The optimal electroporation conditions for gene transfer into CTVTs were tested by luciferase activity and determined to be a voltage of 200 V and duration of 50 msec, with the number of shocks set at 10 pulses, and the use of an electrode with 2 needles. Under these conditions, intratumoral administration of as little as 0.1 mg pIL-12 followed by electroporation significantly inhibited the growth of well-established tumors and eventually led to complete tumor regression. Furthermore, local pIL-12 treatment also induced a strong systemic effect that prevented new tumor growth and cured established tumors at distant locations. Intratumoral administration of pIL-12 greatly elevated the IL-12 level in the tumor masses, but produced only a trace amount in the serum. A high level of IFN-gamma mRNA was also detected in the treated tumor masses. pIL-12 gene therapy attracted significantly more lymphocytes infiltrating the tumors, including CD4(+) and CD8(+) T cells, and the surface expression of MHC I and MHC II molecules on CTVT cells was greatly increased after pIL-12 therapy. This treatment also induced apoptosis of the tumor cells as detected by Annexin V. More importantly, delivery of pIL-12 with intratumoral electroporation did not result in any detectable toxicity in the dogs. We conclude that intratumoral electroporation of the pIL-12 gene could cause profound immunologic host responses and efficiently treat CTVT in beagle dogs. The results also indicate that CTVT is an excellent large animal cancer model for testing immunogene therapies mediated by electroporation.
Chuang
Tien-Fu
TF
Department of Veterinary Medicine, School of Veterinary Medicine, National Taiwan University, Taipei, Taiwan, The Republic of China.
Lee
Shan-Chih
SC
Liao
Kuang-Wen
KW
Hsiao
Ya-Wen
YW
Lo
Chia-Hui
CH
Chiang
Bor-Luen
BL
Lin
Xi-Zhang
XZ
Tao
Mi-Hua
MH
Chu
Rea-Min
RM
D000818:Animals; D017209:Apoptosis; D015496:CD4-Positive T-Lymphocytes; D018414:CD8-Positive T-Lymphocytes; D004195:Disease Models, Animal; D004283:Dog Diseases / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D004285:Dogs; D053672:Electrochemotherapy; D005434:Flow Cytometry; D005805:Genes, MHC Class I / Q000276:immunology; D005802:Genes, MHC Class II / Q000276:immunology; D015316:Genetic Therapy / Q000379:methods*; D007167:Immunotherapy / Q000379:methods*; D007371:Interferon-gamma / Q000032:analysis; D018664:Interleukin-12 / Q000235:genetics* / Q000276:immunology / Q000494:pharmacology* / Q000627:therapeutic use; D009368:Neoplasm Transplantation; D014685:Venereal Tumors, Veterinary / Q000235:genetics / Q000276:immunology / Q000628:therapy*
D018664:Interleukin-12; D007371:Interferon-gamma